Topics:
Thoracic Malignancies • Medical Oncology
How do you discern between pseudo-progression or hyper-progression in patients with NSCLC or cancers treated with immune checkpoint inhibitors?
How common is hyperprogresion, and are there any strategies to mitigate it?
Answer from: Medical Oncologist at Community Practice
This is an excellent question, and the subject of intense debate. Pseudo-progression, or disease that initially grows on immunotherapy only to later regress, is a relatively rare entity in NSCLC. In a retrospective series done by our group, only 2% of patients experienced true pseudo-progression (...
Sign in or Register to read more